Clinical Trial Update: Open Label Extension Study Evaluating Safety and Biological Activity of C2L-OCT-01 PR in Acromegalic Patients [Phase 3]

View source ↗

Summary

An open-label extension study in acromegaly evaluating the safety and biological activity of C2L-OCT-01 PR in a Phase 3 setting has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acromegaly

Drugs mentioned

• C2L-OCT-01 PR

Snippet

Sponsor: Ambrilia Biopharma, Inc. | Conditions: Acromegaly | Phase 3 | Status: COMPLETED